Tag: exemestaneAromasin
Aromasin: An aromatase inhibitor used to treat ER+ breast cancer. Aromatase inhibitors are designed to inhibit the action of the enzyme aromatase, which converts androgens into estrogens within the body. Aromasin is the trade name of exemestane.
Articles
- Aromatase inhibitor treatment and weight gain
- Foods to eat & avoid during aromatase inhibitor treatment
- Impact of endocrine therapy (hormone therapy) on BC prognosis
News
- 04/30/13
- Side effects of anti-estrogens can indicate treatment is working
- 07/17/11
- Increasing aromatase inhibitor side effects make tamoxifen attractive
Studies
-
In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment
Cite
Bezerra PHA, Amaral C, Almeida CF, Correia-da-Silva G, Torqueti MR, Teixeira N. In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment. Molecules. MDPI AG; 2023; 28:4893 10.3390/molecules28134893
-
Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
Cite
Zhang X, Gunda A, Kranenbarg EM, Liefers G, Savitha BA, Shrivastava P, et al. Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01643-2
-
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
Cite
Bradley R, Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, et al. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology. Elsevier BV; 2022; 10.1016/s1470-2045(21)00758-0
-
Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
Cite
Harrigan M, McGowan C, Hood A, Ferrucci LM, Nguyen T, Cartmel B, et al. Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions. Nutrients. MDPI AG; 2021; 13:3730 10.3390/nu13113730
-
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
Cite
Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, et al. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:3152-3165 10.1200/jco.19.01472
-
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
Cite
Li L, Chang B, Jiang X, Fan X, Li Y, Li T, et al. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4878-4
-
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27
Cite
Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, et al. Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2018; 110:1003-1008 10.1093/jnci/djy017
-
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27
Cite
Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd L, O'Shaughnessy J, Parulekar W, et al. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. European Journal of Cancer. Elsevier BV; 2018; 90:19-25 10.1016/j.ejca.2017.11.014
-
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
Cite
Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers G, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2017; 18:1211-1220 10.1016/s1470-2045(17)30419-9
-
Long-Term Follow-Up of the Intergroup Exemestane Study
Cite
Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, et al. Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:2507-2514 10.1200/jco.2016.70.5640
-
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Cite
Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, et al. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:3113-3122 10.1200/jco.2016.72.0946
-
Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04)
Cite
Fontein D, Charehbili A, Nortier J, Putter H, Kranenbarg EM, Kroep J, et al. Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04). European Journal of Surgical Oncology (EJSO). Elsevier BV; 2017; 43:619-624 10.1016/j.ejso.2016.07.146
-
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials
Cite
Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, et al. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2221-2231 10.1200/jco.2015.64.3171
-
Abstract P4-13-07: Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO
Cite
Bloch W, Baumann F, Zimmer P, Grischke E, Fasching P, Decker T, et al. Abstract P4-13-07: Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p4-13-07
-
A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients
Cite
Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, et al. A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients. Cancer Prevention Research. American Association for Cancer Research (AACR); 2016; 9:349-356 10.1158/1940-6207.capr-15-0311
-
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy
Cite
Bellet M, Gray KP, Francis PA, Láng I, Ciruelos E, Lluch A, et al. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:1584-1593 10.1200/jco.2015.61.2259
-
Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer
Cite
Dowsett M, Lønning PE, Davidson NE. Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:1580-1583 10.1200/jco.2015.62.3728
-
Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety
Cite
Gatti-Mays ME, Venzon D, Galbo CE, Singer A, Reynolds J, Makariou E, et al. Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety. Cancer Prevention Research. American Association for Cancer Research (AACR); 2016; 9:225-233 10.1158/1940-6207.capr-15-0269
-
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
Cite
HOLE S, PEDERSEN AM, HANSEN SK, LUNDQVIST J, YDE CW, LYKKESFELDT AE. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. International Journal of Oncology. Spandidos Publications; 2015; 46:1481-1490 10.3892/ijo.2015.2850
-
Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial
Cite
Stearns V, Chapman JW, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, et al. Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:265-271 10.1200/jco.2014.57.6926
-
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients
Cite
Fontein D, Houtsma D, Hille E, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, et al. Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients. Annals of Oncology. Elsevier BV; 2012; 23:3091-3097 10.1093/annonc/mds204
-
Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation
Cite
Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC. Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. British Journal of Cancer. Springer Science and Business Media LLC; 2012; 106:1062-1067 10.1038/bjc.2012.43
-
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
Cite
Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1299-1309 10.1093/jnci/djr242
-
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
Cite
van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel J, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. The Lancet. Elsevier BV; 2011; 377:321-331 10.1016/s0140-6736(10)62312-4
-
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen
Cite
Bertelli G, Hall E, Ireland E, Snowdon C, Jassem J, Drosik K, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen. Annals of Oncology. Elsevier BV; 2010; 21:498-505 10.1093/annonc/mdp358
-
Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
Cite
Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, et al. Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1294-1300 10.1200/jco.2008.21.3553